ADC Landscape
Merck / Kelun-Biotech
TROP2 · NSCLC, breast (broad program)
Phase 3Antibody–Drug Conjugates
Target
TROP2
Payload
T030 (belotecan-deriv.)
Payload class
Topo-I inhibitor
Linker
Cleavable
Indication
NSCLC, breast (broad program)
Phase
Phase 3
Partner
Merck ($+9B deal)
Overview
Merck's TROP2 horse, licensed from China's Kelun for one of biopharma's largest-ever China-out deals. Approved in China; global Phase 3s position it against Datroway & Trodelvy.
Technology
Merck / Kelun-Biotech works in Antibody–Drug Conjugates — A guided missile: an antibody that flies a chemo warhead straight to the tumor.
Read the Antibody–Drug Conjugates brief →Related companies
Daiichi Sankyo
HER2
Gilead
TROP2
AstraZeneca / Daiichi
TROP2
Pfizer (Seagen)
CD30
Pfizer (Seagen)
Nectin-4
Pfizer (Seagen)
Tissue Factor
Company website / source ↗ Open the interactive map →
◢ Boom-cycle briefing
Get ahead of the next biotech boom.
New companies, stage changes, deal alerts and fresh tech briefs — one sharp email when the map moves.
Curated biotech intelligence, compiled for orientation — not investment advice. Company stages, deals and figures move fast; verify against ClinicalTrials.gov, company filings and primary sources before acting.